HUTCHMED's Sovleplenib Receives Priority Review and Breakthrough Designation in China for Rare Blood Disorder
核心洞察
HUTCHMED's sovleplenib, a novel oral Syk (搜索) inhibitor, has received priority review and breakthrough therapy designation from China's NMPA for treating warm antibody autoimmune hemolytic anemia (搜索).
The NDA submission is supported by positive Phase III data showing the drug met its primary endpoint of durable hemoglobin response in patients with wAIHA who failed prior treatments.
Phase II results published in The Lancet Haematology demonstrated a 43.8% overall response rate versus 0% for placebo in the first 8 weeks, with 66.7% response during 24 weeks of treatment.
HUTCHMED announced that China's National Medical Products Administration has accepted its New Drug Application for sovleplenib to treat warm antibody autoimmune hemolytic anemia (搜索), granting both priority review status and breakthrough therapy designation. The oral Syk (搜索) inhibitor targets a rare blood disorder affecting an estimated 17 per 100,000 adults, with limited treatment options available for patients who fail standard glucocorticoid therapy.
Addressing Critical Unmet Medical Need
Warm antibody autoimmune hemolytic anemia (搜索) represents the most common form of autoimmune hemolytic anemia (搜索), accounting for 75-80% of all adult cases. The disorder is characterized by antibody-mediated destruction of red blood cells, with an annual incidence of 0.8-3.0 per 100,000 adults and a mortality rate of 8-11%. The NMPA's breakthrough designation recognizes sovleplenib as a potential treatment for a serious condition lacking effective therapeutic options.
"We are pleased to have submitted the NDA for sovleplenib in wAIHA, securing both Priority Review and Breakthrough Therapy Designation from the NMPA," said Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED. "This marks the second indication for which we have submitted an NDA for sovleplenib and underscores its broad potential as a novel oral Syk (搜索) inhibitor."
Strong Clinical Evidence Supports Regulatory Filing
The NDA submission is backed by data from ESLIM-02, a randomized, double-blind, placebo-controlled Phase II/III study conducted in China. The trial enrolled adult patients with primary or secondary wAIHA who had relapsed or were refractory to at least one prior line of standard treatment. In January 2026, the Phase III portion met its primary endpoint of durable hemoglobin response rate within weeks 5 to 24 of treatment.
Earlier Phase II results, published in The Lancet Haematology in January 2025, demonstrated compelling efficacy signals. The study showed an overall response rate of 43.8% versus 0% for placebo in the first 8 weeks of treatment. During the full 24-week treatment period, including patients who crossed over from placebo, sovleplenib achieved a 66.7% overall response rate while maintaining a favorable safety profile.
Novel Mechanism Targets Disease Pathophysiology
Sovleplenib represents a selective small molecule inhibitor targeting spleen tyrosine kinase (搜索) (Syk (搜索)), a key component in B-cell receptor and Fc receptor signaling pathways. The drug's mechanism directly addresses the pathogenic processes underlying wAIHA, where antibody-coated red blood cells undergo accelerated clearance by macrophages bearing immunoglobulin Fc-gamma receptors.
Activated Syk (搜索) mediates downstream signaling of activated Fc receptors in phagocytic cells, resulting in red blood cell destruction. Additionally, Syk activation through B-cell receptors drives B-lymphocyte activation and differentiation into antibody-secreting plasma cells. By inhibiting Syk, sovleplenib may reduce both phagocytosis and antibody production, targeting multiple aspects of disease pathology.
Expanding Hematology Portfolio
Beyond wAIHA, sovleplenib is advancing through development for immune thrombocytopenia (搜索) (ITP). Positive results from the Phase III ESLIM-01 trial in Chinese patients with primary ITP have been published in The Lancet Haematology. The NMPA accepted a resubmitted NDA for ITP treatment and granted priority review in February 2026.
According to IQVIA data, China has 430,000 existing ITP patients with 41,000 new cases annually. Approximately half of ITP patients fail to achieve satisfactory results with currently approved treatments, including thrombopoietin and thrombopoietin receptor agonists, highlighting the significant unmet medical need.
The Phase III results for wAIHA will be presented at the upcoming European Hematology Association Congress 2026, providing additional clinical data to support the drug's therapeutic potential. HUTCHMED retains worldwide rights to sovleplenib, positioning the company to pursue global development opportunities across multiple hematological indications.